<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        170-325-05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2005
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CLARIMAC 500 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLARITHROMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        51.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="RIYADH PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 407]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01FA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each Clarimac film coated tablet contains 500mg of the active ingredient clarithromycin.</p><p>Clarimac belongs to a group of medicines called macrolide antibiotics. Antibiotics stop the growth of bacteria which cause infections.</p><p>Clarimac film coated tablets are used to treat infections such as:</p><ol><li>Chest infections such as bronchitis and pneumonia</li><li>Throat and sinus infections</li><li>Skin and soft tissue infections</li><li>Helicobacter pylori infection associated with duodenal ulcer.</li></ol><p>&nbsp;</p><p>Clarimac Tablets are indicated for adults and children 12 years and older.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take CLARIMAC film coated tablets if you:</strong></p><ul><li>know that you are <strong>allergic </strong>to clarithromycin, other macrolide antibiotics such as erythromycin or azithromycin, or any of the other ingredients in the tablets.</li><li>are taking medicines called ergot alkaloid tablets (e.g. ergotamine or dihydroergotamine) or use ergotamine inhalers for migraine.</li><li>are taking medicines called terfenadine or astemizole (widely taken for hay fever or allergies) or cisapride or domperidone (for stomach disorders) or pimozide (for mental health problems) as combining these drugs can sometimes cause serious disturbances in heart rhythm. Consult your doctor for advice on alternative medicines</li><li>are taking other medicines which are known to cause serious disturbances in heart rhythm.</li><li>are taking lovastatin or simvastatin (HMG-CoA reductase inhibitors, commonly known as statins, used to lower levels of cholesterol (a type of fat) in the blood).</li><li>are taking oral midazolam (a sedative).</li><li>are taking a medicine containing lomitapide</li><li>have abnormally low levels of potassium or magnesium in your blood (hypokalaemia or hypomagnesaemia).</li><li>have severe liver disease with kidney disease.</li><li><!--[if gte vml 1]><v:rect
      id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
      margin-left:47.45pt;margin-top:-8pt;width:522pt;height:806.85pt;
      z-index:251656704;mso-position-horizontal-relative:page' filled="f"
      strokeweight="1pt">
      <w:wrap anchorx="page"/>
     </v:rect><![endif]-->or someone in your family has a history of heart rhythm disorders (ventricular cardia arrhythmia, including torsades de pointes) or abnormality of electrocardiogram (ECG, electrical recording of the heart) called &ldquo;long QT syndrome&rdquo;.</li><li>are taking medicines called ticagrelor or ranolazine (for heart attack, chest pain or angina)</li><li>are taking colchicine (usually taken for gout)</li></ul><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before taking clarimac film coated Tablets:</p><ul><li>if you have heart problems (e.g., heart disease, heart failure, an unusually slow heart rate)</li><li>if you have any liver or kidney problems</li><li>if you have, or are prone to, fungal infections (e.g. thrush)</li><li>if you are pregnant or breastfeeding</li></ul><p>&nbsp;</p><p>If any of these apply to you, consult your doctor before taking Clarimac film coated tablets.</p><p>If you develop severe or prolonged diarrhoea during or after receiving Clarimac film coated tablets, tell your doctor <strong>immediately</strong>, as this could be a symptom of more serious conditions such as pseudomembranous colitis or clostridium difficile associated diarrhoea.</p><p>If you develop any symptoms of liver dysfunction such as anorexia (loss of appetite), yellowing of the skin or whites of the eyes, dark urine, itching or tender abdomen, stop taking Clarimac film coated tablets and tell your doctor <strong>immediately.</strong></p><p>Long term use of Clarimac film coated tablets may lead to infection with resistant bacteria and fungi.</p><p><strong>&nbsp;</strong></p><p><strong>Children</strong></p><p>Clarimac film coated tablets are not suitable for use in children under 12 years of age.</p><p>&nbsp;</p><p><strong>Other medicines and Clarimac film coated tablets</strong></p><p>You should <strong>not </strong>take Clarimac film coated tablets if you are taking any of the medicines listed in the</p><p>section above &ldquo;Do not take Clarimac film coated tablets if you;&rdquo;</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines as your dose may need to be changed or you may need to have regular tests performed:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;digoxin, quinidine or disopyramide (for heart problems)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ibrutinib (for cancer treatment)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;warfarin, or any other anticoagulant e.g. dabigatran, rivaroxaban, apixaban (for blood thinning)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;carbamazepine, valproate, phenobarbital or phenytoin (for epilepsy)</p><p>&middot;&nbsp; &nbsp; &nbsp; &nbsp; atorvastatin, rosuvastatin (HMG-CoA reductase inhibitors, commonly known as statins, and used to lower levels of cholesterol (a type of fat) in the blood). Statins can cause rhabdomyolysis (a condition which causes the breakdown of muscle tissue which</p><p>&nbsp; &nbsp; &nbsp; &nbsp; can result in kidney damage) and signs of myopathy (muscle pain or muscle weakness) should be monitored.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nateglinide, pioglitazone, repaglinide, rosiglitazone or insulin (used to lower blood glucose levels)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gliclazide or glimepiride (sulphonylureas used in the treatment of type II diabetes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; theophylline (used in patients with breathing difficulties such as asthma)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; triazolam, alprazolam or intravenous or oromucosal midazolam (sedatives)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cilostazol (for poor circulation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methadone (used in the treatment of opioid addiction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methylprednisolone (a corticosteroid)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vinblastine (for treatment of cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ciclosporin, sirolimus and tacrolimus (immune suppressants)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; etravirine, efavirenz, nevirapine, ritonavir, zidovudine, atazanavir, saquinavir (anti-viral drugs used in the treatment of HIV)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifabutin, rifampicin, rifapentine, fluconazole, itraconazole (used in the treatment of certain bacterial infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tolterodine (for overactive bladder)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; verapamil, amlodipine, diltiazem (for high blood pressure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sildenafil, vardenafil and tadalafil (for impotence in adult males or for use in pulmonary arterial hypertension (high blood pressure in the blood vessels of the lung)) St John&rsquo;s Wort (a herbal product used to treat depression)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:rect
 id="_x0000_s1027" style='position:absolute;left:0;text-align:left;
 margin-left:48.75pt;margin-top:-9.8pt;width:522pt;height:806.85pt;z-index:251657728;
 mso-position-horizontal-relative:page' filled="f" strokeweight="1pt">
 <w:wrap anchorx="page"/>
</v:rect><![endif]-->quetiapine or other antipsychotic medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other macrolide medicines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lincomycin and clindamycin (lincosamides &ndash; a type of antibiotic)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hydroxychloroquine or chloroquine (used to treat conditions including rheumatoid arthritis, or to treat or prevent malaria). Taking these medicines at the same time as clarithromycin may increase the chance of you getting side effects that affect your</p><p>&nbsp; &nbsp; &nbsp; &nbsp;heart.</p><p>&nbsp;</p><p>Please tell your doctor if you are taking oral contraceptive pills and diarrhoea or vomiting occurs, as you may need to take extra contraceptive precautions such as using a condom.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist before taking this medicine as the safety of Clarimac Film coated tablets in pregnancy and breast-feeding is not known</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machinery</strong></p><p>Clarimac Film coated tablets may make you feel dizzy or drowsy. If they affect you in this way do not drive, operate machinery or do anything that requires you to be alert.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not give these tablets to children under 12 years. Your doctor will prescribe another suitable medicine for your child.</p><p>&nbsp;</p><p>Always take Clarimac film coated tablets exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. The recommended dose is;</p><p><strong>&nbsp;</strong></p><p><strong>For chest infections, throat or sinus infections and skin and soft tissue infections:</strong></p><p>Clarimac 500mg tablet twice daily in severe infections.</p><p>Clarimac film coated tablets should be swallowed with at least half a glass of water.</p><p>&nbsp;</p><p><strong>For the treatment of Helicobacter pylori infection associated with duodenal ulcers:</strong></p><p>There are a number of effective treatment combinations available to treat Helicobacter pylori in which Clarimac film coated tablets are taken together with one or two other drugs.</p><p>These combinations include the following and are usually taken for 6 to 14 days:</p><p>a) One Clarimac 500mg film coated tablet taken twice a day together with amoxycillin 1000mg taken twice a day with a proton pump inhibitor twice a day.</p><p>b) One Clarimac 500mg film coated tablet taken twice a day together with metronidazole, 400 mg taken twice a day plus a proton pump inhibitor twice a day.</p><p>c) One Clarimac 500mg film coated mg tablet taken twice a day together with amoxycillin 1000 mg taken twice a day or metronidazole, 400 mg taken twice a day plus a proton pump inhibitor once a day.</p><p>&nbsp;</p><p>The treatment combination which you receive may differ slightly from the above. Your doctor will decide which treatment combination is the most suitable for you. If you are unsure which tablets you should be taking or how long you should be taking them for, please consult your doctor for advice.</p><p>&nbsp;</p><p><strong>If you take more Clarimac film coated tablets than you should</strong></p><p>If you accidentally take more tablets in one day than your doctor has told you to, or if a child accidentally swallows some tablets, contact your doctor or nearest hospital emergency department immediately. An overdose of Clarimac film coated tablets is likely to cause vomiting and stomach pains.</p><p>&nbsp;</p><p><strong>If you forget to take Clarimac film coated tablets</strong></p><p>If you forget to take a dose of your tablets, take one as soon as you remember. Do not take more tablets in one day than your doctor has told you to.</p><p>&nbsp;</p><p><strong>If you stop taking Clarimac film coated tablets</strong></p><p>Do not stop taking your tablets, even if you feel better. It is important to take the tablets for as long as the doctor has told you to, otherwise, the problem might come back.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:rect id="_x0000_s1026" style='position:absolute;left:0;
 text-align:left;margin-left:47.3pt;margin-top:-10.3pt;width:522pt;height:806.85pt;
 z-index:251661824;mso-position-horizontal-relative:page' filled="f"
 strokeweight="1pt">
 <w:wrap anchorx="page"/>
</v:rect><![endif]-->If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Clarimac film coated tablets can cause side effects although not everybody gets them.</p><p>If you suffer from any of the following at any time during your treatment STOP TAKING your tablets and contact your doctor immediately:</p><ul><li>severe or prolonged diarrhoea, which may have blood or mucus in it. Diarrhoea may occur over two months after treatment with clarithromycin, in which case you should still contact your doctor.</li><li>a rash, difficulty breathing, fainting or swelling of the face, tongue, lips, eyes and throat. This is a sign that you may have developed an allergic reaction.</li><li>yellowing of the skin (jaundice), skin irritation, pale stools, dark urine, tender abdomen or loss of appetite. These are signs that your liver may have inflammation and not be working properly.</li><li>severe skin reactions such as painful blistering of the skin, mouth, lips, eyes and genitals (symptoms of a rare allergic reaction called Stevens-Johnson syndrome/toxic epidermal necrolysis).</li><li>a red, scaly rash with bumps under the skin and blisters (symptoms of exanthematous pustulosis). The frequency of this side effect is not known (cannot be estimated from the available data).</li><li>rare allergic skin reactions which cause severe illness with ulceration of the mouth, lips and skin which causes severe illness with rash, fever and inflammation of internal organs (DRESS).</li><li>muscle pain or weakness known as rhabdomyolysis (a condition which causes the breakdown of muscle tissue which can result in kidney damage).</li></ul><p><strong>Other side effects </strong></p><p>Common side effects (may affect up to 1 in 10 people) include;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in sense of taste</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; widening of blood vessels</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach problems such as feeling sick, vomiting, stomach pain, indigestion, diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating<strong> </strong></p><p>Uncommon side effects (may include up to 1 in 100 people) include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high temperature</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling, redness or itchiness of the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral or vaginal &lsquo;thrush&rsquo; (a fungal infection)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the stomach and intestines</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease of the levels of blood platelets (blood platelets help stop bleeding)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in white blood cells (leukopenia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in neutrophils (neutropenia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase of eosinophils (white blood cells involved in immunity)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; exaggerated immune response to a foreign agent</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lack or loss of appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety, nervousness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness, tiredness, dizziness or shaking</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; involuntary muscle movements</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vertigo</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears or hearing loss</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain or changes in heart rhythm such as palpitations or an irregular heartbeat</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; asthma: lung disease associated with tightening of air passages, making breathing difficult</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nosebleed</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clot that causes sudden blockage in a lung artery (pulmonary embolism)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lining of the gullet (oesophagus) and lining of the stomach</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anal pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bloating, constipation, wind, burping</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:rect
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:48pt;margin-top:-2.4pt;width:522pt;height:790.8pt;z-index:251655680;
 mso-position-horizontal-relative:page' filled="f" strokeweight="1pt">
 <w:wrap anchorx="page"/>
</v:rect><![endif]-->dry mouth</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; situation where the bile (fluid made by the liver and stored in the gallbladder) cannot flow from the gallbladder to the duodenum (cholestasis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the skin characterized by the presence of the bullae which are filled with fluid, itchy and painful rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms, muscle pain or loss of muscle tissue. If your child suffers from myasthenia gravis (a condition in which the muscles become weak and tire easily), clarithromycin may worsen these symptoms.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised abnormal kidney and liver function blood test and raised blood tests</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak, tired and having no energy</p><p>&nbsp;</p><p>Not known side effects (frequency cannot be estimated from the available data):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the colon</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bacterial infection of the outer layers of the skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in the level of certain blood cells (which can make infections more likely or increase the risk of bruising or bleeding)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion, loss of bearings, hallucinations (seeing things), change in sense of reality or panicking, depression, abnormal dreams or nightmares and mania (feeling of elation or over-excitement)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convulsion (fits)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; paraesthesia, more commonly known as &lsquo;pins and needles&rsquo;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of taste or smell or inability to smell properly</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; type of heart rhythm disorder (Torsade de pointes, ventricular tachycardia)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of blood (haemorrhage)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; discolouration of the tongue or teeth</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acne</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in the levels of products produced by the kidney, inflammation of the kidney or an inability of the kidney to function properly (you may notice tiredness, swelling or puffiness in the face, abdomen, thighs or ankles or problems with urination)</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>If you get any side effects, talk to your doctor, pharmacist. This includes any possible side effects not listed in this leaflet.</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>- Store below 30&deg;C, protect from light.</p><p>- Store in the original pack to protect from moisture.</p><p>- Do not use CLARIMAC Film Coated tablets after the expiry date which is stated on the blister and on the carton.</p><p>- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What CLARIMAC film coated tablets contain</strong></p><p>&nbsp;</p><p>Clarimac Film Coated Tablet contains 500 mg of the active ingredient Clarithromycin (USP).</p><p>The other inactive ingredients are: Maize Starch, Sodium Starch Glycollate, Calcium Hydrogen Phosphate, Hydroxypropyl Cellulose LF, magnesium stearate, talc, colloidal anhydrous silica, and the coating material Opadry Yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CLARIMAC film coated Tablet 500 mg looks yellow capsule shaped, biconvex film coated tablets with MC41 on one side and plain on the other side.

Pack size:  
Clarimac film coated tablet 500 mg white PVC – PVDC film Aluminum foil blister pack of 7 film coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)</p><p>P.O.Box 442, Riyadh 11411</p><p>Fax: +966 11 265 0505</p><p>Email: contact@riyadhpharma.com</p><p><em>For any information about this medicinal product, please contact the local representative of marketing authorisation holder:</em></p><p>Saudi Arabia</p><p>Marketing department</p><p>Riyadh</p><p>Tel: +966 11 265 0111</p><p>Email: marketing@riyadhpharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي كل قرص مغلف من كلاريماك على 500 ملجم من المادة الفعالة كلاريثرومايسن.</p><p dir="RTL">ينتمي كلاريماك إلى مجموعة من الأدوية تسمى المضادات الحيوية ماكرولايد. المضادات الحيوية توقف نمو البكتيريا التي تسبب العدوى.</p><p dir="RTL">تستخدم أقراص كلاريماك المغلفة في علاج العدوى مثل:</p><p dir="RTL">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الصدر مثل التهاب الشعب الهوائية والالتهاب الرئوي</p><p dir="RTL">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الحلق والجيوب الأنفية</p><p dir="RTL">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجلد والأنسجة الرخوة</p><p dir="RTL">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى هيليكوباكتر بيلوري المصاحبة لقرحة الاثني عشر</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم وصف أقراص كلاريماك للبالغين والأطفال بعمر 12 عامًا فما فوق.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول أقراص كلاريماك المغلفة إذا كنت</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعلم أن لديك <strong>حساسية</strong> تجاه كلاريثروميسين، أو المضادات الحيوية الأخرى من نوع ماكرولايد مثل إريثرومايسين أو أزيثروميسين، أو أي من المكونات الأخرى الموجودة في الأقراص.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدوية تسمى أقراص قلويدات الإرغوت (مثل الإرغوتامين أو ثنائي هيدروأرغوتامين) أو تستخدم أجهزة استنشاق الإرغوتامين لعلاج الصداع النصفي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدوية تسمى تيرفينادين أو أستيميزول (تُستخدم على نطاق واسع لعلاج حمى القش أو الحساسية) أو سيسابريد أو دومبيريدون (لاضطرابات المعدة) أو بيموزيد (لمشاكل الصحة العقلية) لأن الجمع بين هذه الأدوية يمكن أن يسبب أحيانًا اضطرابات خطيرة في ضربات القلب. استشر طبيبك للحصول على المشورة بشأن الأدوية البديلة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول أدوية أخرى معروفة بأنها تسبب اضطرابات خطيرة في نظم القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول لوفاستاتين أو سيمفاستاتين (مثبطات إنزيم اختزال HMG-CoA، المعروفة باسم الستاتينات، والتي تستخدم لخفض مستويات الكوليسترول (نوع من الدهون) في الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول الميدازولام عن طريق الفم (مهدئ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول &nbsp;دواء يحتوي على لوميتابيد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك مستويات منخفضة بشكل غير طبيعي من البوتاسيوم أو الماغنيسيوم في الدم (نقص بوتاسيوم الدم أو نقص ماغنسيوم الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بأمراض الكبد الشديدة مع أمراض الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو لدى أحد أفراد عائلتك تاريخ من اضطرابات ضربات القلب(عدم انتظام ضربات القلب البطيني، بما في ذلك torsades de &nbsp;pointes &nbsp;) أو خلل في مخطط كهربية القلب (التسجيل الكهربائي للقلب) يسمى &quot;متلازمة QT الطويلة&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:rect
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:25.15pt;margin-top:-7.1pt;width:547.2pt;height:805.8pt;z-index:251656704;
 mso-position-horizontal-relative:page' filled="f" strokeweight=".5pt">
 <w:wrap anchorx="page"/>
</v:rect><![endif]-->تتناول أدوية تسمى تيكاجريلور أو رانولازين (لعلاج الأزمة القلبية أو ألم الصدر أو الذبحة الصدرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتناول دواء كولشيسين (عادةً ما يتم تناوله لعلاج النقرس).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي أو الممرضة قبل تناول أقراص كلاريماك المغلفة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في القلب (مثل أمراض القلب، وقصور القلب، وبطء معدل ضربات القلب بشكل غير عادي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي مشاكل في الكبد أو الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا أو معرضًا للإصابة بالعدوى الفطرية (مثل مرض القلاع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً أو مرضعة</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا انطبقت أي من هذه الحالات عليك ، فاستشر طبيبك قبل تناول أقراص كلاريماك المغلفة.</p><p dir="RTL">إذا أصبت بإسهال شديد أو طويل الأمد أثناء أو بعد تناول أقراص كلاريماك المغلفة ، أخبر طبيبك <strong>على الفور</strong> ، لأن هذا قد يكون أحد أعراض الحالات الأكثر خطورة مثل التهاب القولون الغشائي الكاذب أو المطثية العسيرة المصحوبة بالإسهال.</p><p dir="RTL">إذا ظهرت لديك أي أعراض لخلل في وظائف الكبد مثل فقدان الشهية (فقدان الرغبة في الأكل) ، اصفرار الجلد أو بياض العينين ، بول داكن ، حكة أو ألم في البطن ، توقف عن تناول أقراص كلاريماك المغلفة وأخبر طبيبك <strong>على الفور</strong>.</p><p dir="RTL">قد يؤدي الاستخدام طويل الأمد لأقراص كلاريماك المغلفة إلى الإصابة بالبكتيريا والفطريات المقاومة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">أقراص كلاريماك المغلفة غير مناسبة للاستخدام لدى الأطفال أقل من 12 عامًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى وأقراص كلاريماك المغلفة</strong></p><p dir="RTL">يجب <strong>ألا </strong>تتناول أقراص كلاريماك المغلفة إذا كنت تتناول أيًا من الأدوية المدرجة في القسم أعلاه &quot;لا تتناول أقراص كلاريماك المغلفة إذا كنت:&quot;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى حيث قد تحتاج إلى تغيير جرعتك أو قد تحتاج إلى إجراء اختبارات بصفة منتظمة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين، كينيدين أو ديسوبيراميد (لمشاكل القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبروتينيب (لعلاج السرطان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوارفارين، أو أي مضاد تخثر آخر، على سبيل المثال. دابيجاتران، ريفاروكسابان، أبيكسابان (لعلاج ترقق الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين، فالبروات، الفينوباربيتال أو الفينيتوين (لعلاج الصرع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أتورفاستاتين، رسيوفاستاتين (مثبطات إنزيم اختزال HMG-CoA، المعروفة باسم الستاتينات، وتستخدم لخفض مستويات الكوليسترول (نوع من الدهون) في الدم). يمكن أن تسبب الستاتينات انحلال الربيدات (وهي حالة تسبب انهيار الأنسجة العضلية مما قد يؤدي إلى تلف&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; الكلى) ويجب مراقبة علامات الاعتلال العضلي (ألم في العضلات أو ضعف العضلات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ناتيجلينيد، بيوجليتازون، ريباجلينيد، روزيجليتازون أو الأنسولين (يستخدم لخفض مستويات السكر في الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جليكلازيد أو جليميبيريد (سلفونيل يوريا المستخدمة في علاج مرض السكري من النوع الثاني)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الثيوفيلين (يستخدم في المرضى الذين يعانون من صعوبات في التنفس مثل الربو)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تريازولام، ألبرازولام أو الميدازولام الوريدي أو الفموي المخاطي (المهدئات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلوستازول (لضعف الدورة الدموية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الميثادون (يستخدم في علاج إدمان المواد الأفيونية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثيل بريدنيزولون (كورتيكوستيرويد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينبلاستين (لعلاج السرطان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين، سيروليموس وتاكروليموس (مثبطات المناعة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إترافيرين، إيفافيرينز، نيفيرابين، ريتونافير، زيدوفودين، أتازانافير، ساكوينافير (أدوية مضادة للفيروسات تستخدم في علاج فيروس نقص المناعة البشرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفابوتين، ريفامبيسين، ريفابنتين، فلوكونازول، إيتراكونازول (يستخدم في علاج بعض أنواع العدوى البكتيرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تولتيرودين (لعلاج فرط نشاط المثانة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيراباميل، أملوديبين، ديلتيازيم (لارتفاع ضغط الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلدينافيل، فاردينافيل، وتادالافيل (للعجز الجنسي عند الذكور البالغين أو للاستخدام في ارتفاع ضغط الدم الشرياني الرئوي (ارتفاع ضغط الدم في الأوعية الدموية في الرئة)) نبتة سانت جون (منتج عشبي يستخدم لعلاج الاكتئاب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكيوتيابين أو الأدوية الأخرى المضادة للذهان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية الماكرولايد الأخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لينكومايسين وكليندامايسين (لينكوساميد &ndash; نوع من المضادات الحيوية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيدروكسي كلوروكوين أو كلوروكين (يستخدم لعلاج حالات تتضمن التهاب المفاصل الروماتويدي، أو لعلاج الملاريا أو الوقاية منها). إن تناول هذه الأدوية في نفس الوقت مع كلاريثروميسين قد يزيد من فرصة إصابتك بآثار جانبية تؤثر على قلبك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يرجى إخبار طبيبك إذا كنت تتناولين أقراص منع الحمل وحدث لديك إسهال أو قيء، حيث قد تحتاجين إلى اتخاذ احتياطات إضافية لمنع الحمل مثل استخدام الواقي الذكري.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p>&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:rect id="_x0000_s1026" style='position:absolute;
 left:0;text-align:left;margin-left:24.15pt;margin-top:-4.6pt;width:547.2pt;
 height:800.15pt;z-index:251660800;mso-position-horizontal-relative:page'
 filled="f" strokeweight=".5pt">
 <w:wrap anchorx="page"/>
</v:rect><![endif]-->إذا كنت حاملاً أو مرضعة، أو تعتقدين أنك حامل أو تخططين لإنجاب طفل، اسألي طبيبك أو الصيدلي قبل تناول هذا الدواء حيث أن سلامة أقراص كلاريماك المغلفة أثناء الحمل والرضاعة غير معروفة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة و استخدام الآلات</strong></p><p dir="RTL">قد تجعلك أقراص كلاريماك المغلفة تشعر بالدوار أو النعاس. إذا أثرت عليك بهذه الطريقة، فلا تقم بالقيادة أو تشغيل الآلات أو القيام بأي شيء يتطلب منك الحذر.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تعطي هذه الأقراص للأطفال أقل من 12 عامًا. سيصف طبيبك دواء آخر مناسب لطفلك.</p><p dir="RTL">تناول دائمًا أقراص كلاريماك المغلفة تمامًا كما أخبرك طبيبك. يجب عليك مراجعة طبيبك أو الصيدلي إذا لم تكن متأكدًا. الجرعة الموصى بها هي:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعدوى الصدر و الحلق والجيوب الأنفية والتهابات الجلد والأنسجة الرخوة:</strong></p><p dir="RTL">قرص واحد من كلاريماك 500 ملجم مرتين يوميًا في حالات العدوى الشديدة.</p><p dir="RTL">يجب ابتلاع أقراص كلاريماك المغلفة مع نصف كوب ماء على الأقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج عدوى هيليكوباكتر بيلوري المصاحبة لقرحة الاثني عشر:</strong></p><p dir="RTL">هناك عدد من تركيبات العلاج الفعالة المتاحة لعلاج هيليكوباكتر بيلوري حيث يتم تناول أقراص كلاريماك المغلفة مع واحد أو اثنين من الأدوية الأخرى.</p><p dir="RTL">تتضمن هذه المجموعات ما يلي ويتم تناولها عادةً لمدة تتراوح من 6 إلى 14 يومًا:</p><p dir="RTL">أ) قرص واحد مغلف من كلاريماك 500 ملجم يتم تناوله مرتين في اليوم مع أموكسيسيلين 1000 ملجم يتم تناوله مرتين في اليوم مع مثبط مضخة البروتون مرتين في اليوم.</p><p dir="RTL">ب) قرص واحد مغلف من كلاريماك 500 ملجم يتم تناوله مرتين يومياً مع ميترونيدازول400 ملجم يتم تناوله مرتين يومياً بالإضافة إلى مثبط مضخة البروتون مرتين يومياً.</p><p dir="RTL">ج) قرص واحد مغلف من كلاريماك 500 ملجم يتم تناوله مرتين في اليوم مع أموكسيسيلين 1000 ملجم يتم تناوله مرتين في اليوم أو ميترونيدازول 400 ملجم مرتين في اليوم بالإضافة إلى مثبط مضخة البروتون مرة في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تختلف تركيبة العلاج التي تتلقاها قليلاً عما سبق. سيقرر طبيبك تركيبة العلاج الأنسب لك. إذا لم تكن متأكدًا من الأقراص التي يجب أن تتناولها أو كم من الوقت يجب أن تتناولها ، فيرجى استشارة طبيبك للحصول على المشورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت أقراص كلاريماك المغلفة أكثر مما يجب</strong></p><p dir="RTL">إذا تناولت عن طريق الخطأ أقراصًا في يوم واحد أكثر مما أخبرك به طبيبك ، أو إذا ابتلع طفل عن طريق الخطأ بعض الأقراص ، فاتصل بطبيبك أو أقرب قسم طوارئ في المستشفى على الفور. جرعة زائدة من أقراص كلاريماك المغلفة من المحتمل أن تسبب القيء وآلام في المعدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول أقراص كلاريماك المغلفة</strong></p><p dir="RTL">إذا نسيت تناول جرعة من أقراصك ، فتناول جرعة حالما تتذكرها. لا تتناول أقراصًا في يوم واحد أكثر مما أخبرك طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول أقراص كلاريماك المغلفة</strong></p><p dir="RTL">لا تتوقف عن تناول أقراصك ، حتى لو شعرت بتحسن. من المهم تناول الأقراص طالما طلب منك الطبيب ذلك ، وإلا فقد تعود المشكلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي أو الممرضة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن تسبب أقراص كلاريماك المغلفة آثارًا جانبية على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">إذا كنت تعاني من أي مما يلي في أي وقت أثناء العلاج، توقف عن تناول أقراصك واتصل بطبيبك على الفور:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال الشديد أو المطول، والذي قد يحتوي على دم أو مخاط. قد يحدث الإسهال على مدى شهرين بعد العلاج بكلاريثروميسين، وفي هذه الحالة يجب عليك الاتصال بطبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، صعوبة في التنفس، إغماء أو تورم في الوجه واللسان والشفتين والعينين والحنجرة. هذه علامة على أنك قد تكون قد طورت رد فعل تحسسي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد (يرقان)، تهيج الجلد، براز شاحب، بول داكن، ألم في البطن أو فقدان الشهية. هذه علامات على أن كبدك قد يكون مصابًا بالالتهاب ولا يعمل بشكل صحيح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية حادة مثل تقرحات مؤلمة في الجلد والفم والشفتين والعينين والأعضاء التناسلية (أعراض رد فعل تحسسي نادر يسمى متلازمة ستيفنز جونسون/انحلال البشرة السمي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أحمر متقشر مع نتوءات وبثور تحت الجلد (أعراض البثار الطفحي). معدل تكرار هذا التأثير الجانبي غير معروف (لا يمكن تقديره من البيانات المتاحة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:rect
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:24pt;margin-top:-10.8pt;width:547.2pt;height:805.8pt;z-index:251661824;
 mso-position-horizontal-relative:page' filled="f" strokeweight=".5pt">
 <w:wrap anchorx="page"/>
</v:rect><![endif]-->تفاعلات حساسية جلدية نادرة تسبب مرضًا شديدًا مع تقرح في الفم والشفتين والجلد مما يسبب مرضًا شديدًا مع طفح جلدي وحمى والتهاب الأعضاء الداخلية &nbsp;(DRESS).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو ضعف في العضلات يُعرف باسم انحلال الربيدات (وهي حالة تسبب انهيار الأنسجة العضلية مما قد يؤدي إلى تلف الكلى).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى :</strong></p><p dir="RTL">الآثارالجانبية الشائعة (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص) تشمل ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في حاسة التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتساع الأوعية الدموية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في المعدة مثل الشعور بالغثيان، القيء، آلام في المعدة، عسر الهضم، الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التعرق</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية غير الشائعة (قد تؤثر ما يصل إلى شخص واحد من كل 100 شخص) تشمل ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; درجة حرارة عالية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم، احمرار أو حكة في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض القلاع الفموي أو المهبلي (عدوى فطرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المعدة والأمعاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصفائح الدموية (تساعد الصفائح الدموية على وقف النزيف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في خلايا الدم البيضاء (نقص الكريات البيض)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في العدلات (قلة العدلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الحمضات (خلايا الدم البيضاء المشاركة في المناعة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاستجابة المناعية المبالغ فيها لعامل أجنبي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة أو فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق والعصبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس، التعب، الدوخة أو الاهتزاز</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات لا إرادية في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طنين في الأذنين أو فقدان السمع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر أو تغيرات في ضربات القلب مثل الخفقان أو عدم انتظام ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الربو: مرض رئوي يصاحبه ضيق في الممرات الهوائية مما يجعل التنفس صعباً</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطة دموية تسبب انسدادًا مفاجئًا في شريان الرئة (الانصمام الرئوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بطانة المريء (المريء) وبطانة المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الشرج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانتفاخ، الإمساك، الرياح، التجشؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحالة التي لا يمكن فيها للصفراء (السائل الذي يصنعه الكبد ويخزنه في المرارة) التدفق من المرارة إلى الاثني عشر (ركود صفراوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد الذي يتميز بوجود الفقاعات التي تمتلئ بها طفح جلدي سائل، مثير للحكة ومؤلم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات عضلية، آلام عضلية أو فقدان الأنسجة العضلية. إذا كان طفلك يعاني من الوهن العضلي الوبيل (وهي حالة تصبح فيها العضلات ضعيفة وتتعب بسهولة)، فقد يؤدي كلاريثروميسين إلى تفاقم هذه الأعراض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع غير طبيعي في وظائف الكلى والكبد في فحص الدم وارتفاع في اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف والتعب وانعدام الطاقة</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">غير معروفة (لا يمكن تقدير التكرار من البيانات المتاحة):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى القولون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة البكتيرية بالطبقات الخارجية من الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى بعض خلايا الدم (مما قد يزيد احتمال الإصابة بالعدوى أو يزيد من خطر الإصابة بالكدمات أو النزيف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتباك، فقدان الاتجاه، الهلوسة (رؤية الأشياء)، تغير الإحساس بالواقع أو الذعر والاكتئاب والأحلام غير الطبيعية أو الكوابيس والهوس (الشعور بالابتهاج أو الإثارة المفرطة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات (نوبات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:rect
 id="_x0000_s1027" style='position:absolute;left:0;text-align:left;
 margin-left:24.2pt;margin-top:.75pt;width:547.2pt;height:705.4pt;z-index:251662848;
 mso-position-horizontal-relative:page' filled="f" strokeweight=".5pt">
 <w:wrap anchorx="page"/>
</v:rect><![endif]-->تنمل الحس، المعروف أكثر باسم &quot;الدبابيس والإبر&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان حاسة التذوق أو الشم أو عدم القدرة على الشم بشكل سليم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوع من اضطراب ضربات القلب (تورساد دي بوينت ، عدم انتظام دقات القلب البطيني)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الدم (النزيف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون اللسان أو الأسنان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حَبُّ الشّبَاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في مستويات المنتجات التي تنتجها الكلى، التهاب في الكلى أو عدم قدرة الكلى على القيام بوظائفها بشكل صحيح (قد تلاحظ تعب، تورم أو انتفاخ في الوجه، البطن، الفخذين أو الكاحلين أو مشاكل في التبول).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا ظهرت عليك أي آثار جانبية، تحدث مع طبيبك أو الصيدلي. وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ظروف تخزين أقراص كلاريماك المغلفة</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي و نظر الأطفال.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية. بعيداً عن الضوء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم أقراص كلاريماك المغلفة بعد تاريخ انتهاء الصلاحية المذكور على الشريط أو العبوة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص كلاريماك المغلفة تحتوي على 500 ملجم من المادة الفعالة كلاريثرومايسن (دستور الأدوية الأمريكي).</p><p dir="RTL">المكونات الأخرى غير الفعالة : نشا الذرة، جليكولات صوديوم النشا ، الكالسيوم الهيدروجين الفوسفات، هيدروكسي بروبايل سيليلوز LF، ستيرات المغنيسيوم، التلك، السيليكا اللامائية الغروية ، والمادة المغلفة اوبادري الأصفر.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص كلاريماك 500 &nbsp;ملجم المغلفة</p><p dir="RTL">على شكل كبسولة صفراء ، ثنائية التحدب مع MC41 على جانب واحد و منبسط على الجانب الآخر.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>حجم العبوة</strong><strong>:</strong></p><p dir="RTL">أقراص كلاريماك 500 &nbsp;ملجم المغلفة في</p><p dir="RTL">&nbsp;شريط أبيض (PVDC-PVC/Alu) يحتوي على 7 &nbsp;أقراص مغلفة .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة المنتجات الطبية والتجميلية المحدودة ( الرياض فارما)</p><p dir="RTL">ص.ب. 442 الرياض 11411</p><p dir="RTL">فاكس: 966112650505+</p><p dir="RTL">البريد الإلكتروني: contact@riyadhpharma.com</p><p dir="RTL"><em>لأية معلومات عن هذا المنتج الطبي، يرجى الاتصال على&nbsp; صاحب الترخيص والتسويق:</em></p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">قسم التسويق</p><p dir="RTL">الرياض</p><p dir="RTL">تلفون: 966112650111+</p><p dir="RTL">البريد الإلكتروني: marketing@riyadhpharma.com</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            10/2023
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clarimac 500 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 500 mg of clarithromycin
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clarimac 500 mg : Yellow Capsule shaped , biconvex film coated tablets with MC 41 on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clarithromycin is indicated for treatment of infections due to susceptible organisms. Such infections include.</p><ol><li>Lower respiratory tract infections (e.g. bronchitis, pneumonia) (see section 4.4 and 5.1 regarding Sensitivity Testing).</li><li>Upper respiratory tract infections (e.g. pharyngitis, sinusitis).</li><li>Skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas) (see section 4.4 and 5.1 regarding Sensitivity Testing).</li><li>Disseminated or localised mycobacterial infections due to <em>Mycobacterium avium </em>or <em>Mycobacterium intracellulare</em>.</li></ol><p>Localised infections due to <em>Mycobacterium chelonae</em>, <em>Mycobacterium fortuitum </em>or <em>Mycobacterium kansasii</em>.</p><ol><li>Clarithromycin is indicated for the prevention of disseminated <em>Mycobacterium avium </em>complex infection in HIV-infected patients with CD4 lymphocyte counts less than or equal to 100/mm3.</li><li>Clarithromycin in the presence of acid suppression is indicated for the eradication <em>of H. pylori</em>, resulting in decreased recurrence of duodenal ulcer (see Further Information below).</li></ol><p>&nbsp;</p><p>Clarithromycin tablets are indicated in adults and children 12 years and older.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p><p>&nbsp;</p><p>As with other antibiotics, it is recommended that guidelines on the prevalence of local resistance, and associated medical practice regarding the prescription of antibiotics, be consulted before prescribing Clarimac.</p><p><strong>&nbsp;</strong></p><p><strong>Further Information</strong>: <em>H. pylori </em>is strongly associated with peptic ulcer disease. Ninety to 100% of patients with duodenal ulcers are infected with this agent. Eradication of <em>H. pylori </em>has been shown to markedly reduce the</p><p>rate of duodenal ulcer recurrence, thereby reducing the need for maintenance anti-secretory therapy.</p><p>&nbsp;</p><p>In a well controlled double-blind study, <em>H. pylori </em>infected patients with duodenal ulcer received clarithromycin 500mg t.i.d for 14 days with omeprazole 40mg daily for 28 days.</p><p>&nbsp;</p><p>Clarithromycin has been used in other treatment regimens for the eradication of <em>H. pylori</em>. These regimens include clarithromycin plus tinidazole and omeprazole, and clarithromycin plus tetracycline, bismuth subsalicylate, and</p><p>ranitidine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adults</strong>: The usual recommended dosage of clarithromycin in adults is one 250mg tablet twice daily. In more severe infections, the dosage can be increased to 500mg twice daily. The usual duration of therapy is 6 to 14 days.</p><p>&nbsp;</p><p><strong>Children</strong> <strong>under 12 years:</strong> The use of clarithromycin tablets has not been studied in children under 12 years. Clinical trials have been conducted using clarithromycin paediatric suspension in children 6 months to 12 years of age.</p><p>Therefore, children under 12 years of age should use clarithromycin paediatric suspension (granules for oral suspension).</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>Children over 12 years</strong>: As for adults.</p><p>&nbsp;</p><p>In patients with renal impairment with creatinine clearance less than 30 ml/min, the dosage of clarithromycin should be reduced by one-half, i.e., 250mg once daily, or 250mg twice daily in more severe infections. Treatment</p><p>should not be continued beyond 14 days in these patients.</p><p>&nbsp;</p><p><em>Dosage in patients with mycobacterial infections:</em> The recommended dose for adults with mycobacterial infections is 500mg b.i.d. Treatment of disseminated Mycobacterium Avium Complex (MAC) infections in AIDS</p><p>patients should be continued, as long as clinical microbiological benefit is demonstrated. Clarithromycin should be used in conjunction with other antimycobacterial agents.</p><p>&nbsp;</p><p>Treatment of other non-tuberculous mycobacterial infections should continue at the discretion of the physician.</p><p>&nbsp;</p><p>Dosage for MAC prophylaxis: The recommended dosage of clarithromycin in adults is 500mg twice daily.</p><p>&nbsp;</p><p><em>Eradication of H. pylori</em>:</p><p>Triple Therapy (7 days):</p><p>Clarithromycin (500mg) twice daily and a proton pump inhibitor (at the approved daily dose)* should be given with amoxycillin 1000mg twice daily for 7 days.</p><p>&nbsp;</p><p>Triple Therapy (7 days):</p><p>Clarithromycin (500mg) twice daily and a proton pump inhibitor (at the approved daily dose)* should be given with metronidazole 400mg twice daily for 7 days.</p><p>&nbsp;</p><p>Triple Therapy (7-10 days):</p><p>Clarithromycin (500mg) twice daily should be given with omeprazole 20 mg daily and amoxycillin 1000mg twice daily for 7 to 10 days.</p><p>* see individual data sheets/ SPCs for the dose recommended for H. pylori eradication.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to macrolide antibiotic drugs or any of the excipients (listed in section 6.1).

Concomitant administration of clarithromycin and any of the following drugs is contraindicated: astemizole, cisapride, domperidone, pimozide or terfenadine as this may result in QT prolongation and cardiac arrhythmias,
including ventricular tachycardia, ventricular fibrillation, and torsades de pointes (see section 4.4 and 4.5).

Concomitant administration with ticagrelor or ranolazine is contraindicated.
Concomitant administration of clarithromycin and ergot alkaloids (e.g. ergotamine or dihydroergotamine) is contraindicated, as this may result in ergot toxicity (see section 4.5).

Clarithromycin should not be given to patients with history of QT prolongation (congenital or documented acquired QT prolongation) or ventricular cardiac arrhythmia, including torsades de pointes (see sections 4.4
and 4.5).

Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors (statins), that are extensively metabolised by CYP3A4, (lovastatin or simvastatin), due to the increased risk of myopathy, including
rhabdomyolysis (see section 4.4).

As with other strong CYP3A4 inhibitors, clarithromycin should not be used in patients taking colchicine (see sections 4.4 and 4.5).

Concomitant administration of clarithromycin and oral midazolam is contraindicated (see section 4.5).

Clarithromycin should not be given to patients with hypokalaemia (risk of prolongation of QT-time).

Clarithromycin should not be used in patients who suffer from severe hepatic failure in combination with renal impairment.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The physician should not prescribe clarithromycin to pregnant women without carefully weighing the benefits against risk, particularly during the first three months of pregnancy (see section 4.6).</p><p>&nbsp;</p><p>Clarithromycin is principally metabolised by the liver. Therefore, caution should be exercised in administering the antibiotic to patients with impaired hepatic function. Caution should also be exercised when administering</p><p>clarithromycin to patients with moderate to severe renal impairment.</p><p>&nbsp;</p><p>Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported with clarithromycin. This hepatic dysfunction may be severe and is usually</p><p>reversible. In some instances, hepatic failure with fatal outcome has been reported and generally has been associated with serious underlying diseases and/or concomitant medications. Discontinue clarithromycin immediately if signs and symptoms of hepatitis occur, such as anorexia, jaundice, dark urine,</p><p>pruritus, or tender abdomen.</p><p>&nbsp;</p><p>Cases of fatal hepatic failure (see section 4.8) have been reported. Some patients may have had pre-existing hepatic disease or may have been taking other hepatotoxic medicinal products. Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop, such as anorexia, jaundice, dark urine, pruritus, or tender abdomen.</p><p>&nbsp;</p><p>Pseudomembranous colitis has been reported with nearly all antibacterial agents, including macrolides, and may range in severity from mild to lifethreatening.</p><p><em>&nbsp;</em></p><p><em>Clostridium difficile </em>associated diarrhoea (CDAD) has been reported with use of nearly all antibacterial agents including clarithromycin, and may range in severity from mild diarrhoea to fatal colitis. Treatment with</p><p>antibacterial agents alters the normal flora of the colon, which may lead to overgrowth of C. <em>difficile</em>. CDAD must be considered in all patients who present with diarrhoea following antibiotic use. Careful medical history is</p><p>necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. Therefore discontinuation of clarithromycin therapy should be considered regardless of the indication.</p><p>Microbial testing should be performed and adequate treatment initiated. Drugs inhibiting peristalsis should be avoided.</p><p><u>Colchicine</u></p><p>There have been post-marketing reports of colchicine toxicity with concomitant use of clarithromycin and colchicine, especially in the elderly, some of which occurred in patients with renal insufficiency. Deaths have been</p><p>reported in some such patients (see section 4.5). Concomitant administration of clarithromycin and colchicine is contraindicated (see section 4.3).</p><p>&nbsp;</p><p>Caution is advised regarding concomitant administration of clarithromycin and triazolobenzodiazepines, such as triazolam and intravenous or oromucosal midazolam (see section 4.5).</p><p>&nbsp;</p><p><u>Cardiovascular Events</u></p><p>Prolongation of the QT interval, reflecting effects on cardiac repolarization imparting a risk of developing cardiac arrhythmia and torsade de pointes, have been seen in patients treated with macrolides including clarithromycin (see section 4.8). Due to increased risk of QT prolongation and ventricular arrhythmias (including torsade de pointes), the use of clarithromycin is contraindicated: in patients taking any of astemizole, cisapride, domperidone,</p><p>pimozide and terfenadine; in patients who have hypokalaemia; and in patients with a history of QT prolongation or ventricular cardiac arrhythmia (see section 4.3).</p><p>&nbsp;</p><p>Furthermore, clarithromycin should be used with caution in the following:</p><ul><li>Patients with coronary artery disease, severe cardiac insufficiency, conduction disturbances or clinically relevant bradycardia.</li><li>Patients with hypomagnesaemia;</li><li>Patients concomitantly taking other medicinal products associated with QT prolongation other than those which are contraindicated.</li></ul><p>Epidemiological studies investigating the risk of adverse cardiovascular outcomes with macrolides have shown variable results. Some observational studies have identified a rare short-term risk of arrhythmia, myocardial</p><p>infarction and cardiovascular mortality associated with macrolides including clarithromycin. Consideration of these findings should be balanced with treatment benefits when prescribing clarithromycin.</p><p>&nbsp;</p><p><u>Pneumonia</u>: In view of the emerging resistance of <em>Streptococcus pneumoniae </em>to macrolides, it is important that sensitivity testing be performed when<em> </em>prescribing clarithromycin for community-acquired pneumonia. In hospitalacquired<em> </em>pneumonia, clarithromycin should be used in combination with<em> </em>additional appropriate antibiotics.</p><p>&nbsp;</p><p><u>Skin and soft tissue infections of mild to moderate severity</u>: These infections are most often caused by <em>Staphylococcus aureus </em>and <em>Streptococcus pyogenes</em>, both of which may be resistant to macrolides. Therefore, it is important that sensitivity testing be performed. In cases where <em>beta</em>&ndash;lactam antibiotics cannot be used (e.g. allergy), other antibiotics, such as clindamycin, may be the drug of first choice. Currently, macrolides are only considered to play a role in some skin and soft tissue infections, such as those caused by <em>Corynebacterium</em></p><p><em>minutissimum</em>, acne vulgaris, and erysipelas and in situations where penicillin treatment cannot be used.</p><p>&nbsp;</p><p>In the event of severe acute hypersensitivity reactions, such as anaphylaxis, severe cutaneous adverse reactions (SCAR) (e.g. acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome, toxic epidermal necrolysis and drug rash with eosinophilia and systemic symptoms (DRESS)), clarithromycin therapy should be discontinued immediately and appropriate treatment should be urgently initiated.</p><p>&nbsp;</p><p>Clarithromycin should be used with caution when administered concurrently with medications that induce the cytochrome CYP3A4 enzyme (see section 4.5).</p><p><u>HMG-CoA reductase inhibitors (statins):</u> Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated (see section 4.3).</p><p>&nbsp;</p><p>Caution should be exercised when prescribing clarithromycin with other statins. Rhabdomyolysis has been reported in patients taking clarithromycin and statins. Patients should be monitored for signs and symptoms of</p><p>myopathy. In situations where the concomitant use of clarithromycin with statins cannot be avoided, it is recommended to prescribe the lowest registered dose of the statin. Use of a statin that is not dependent on CYP3A metabolism (e.g. fluvastatin) can be considered (see section 4.5).</p><p>&nbsp;</p><p><u>Oral hypoglycaemic agents/insulin:</u> The concomitant use of clarithromycin and oral hypoglycaemic agents (such as sulphonylurias) and/or insulin can result in significant hypoglycaemia. Careful monitoring of glucose is</p><p>recommended (see section 4.5).</p><p>&nbsp;</p><p><u>Oral anticoagulants</u>: There is a risk of serious haemorrhage and significant elevations in International Normalised Ratio (INR) and prothrombin time when clarithromycin is co-administered with warfarin (see section 4.5). INR</p><p>and prothrombin times should be frequently monitored while patients are receiving clarithromycin and oral anticoagulants concurrently.</p><p>&nbsp;</p><p>Use of any antimicrobial therapy, such as clarithromycin, to treat <em>H. pylori </em>infection may select for drug-resistant organisms.</p><p>&nbsp;</p><p>Long-term use may, as with other antibiotics, result in colonisation with increased numbers of non-susceptible bacteria and fungi. If superinfections occurs, appropriate therapy should be instituted.</p><p>&nbsp;</p><p>Attention should also be paid to the possibility of cross resistance between clarithromycin and other macrolide drugs, as well as lincomycin and clindamycin.</p><p>&nbsp;</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>The use of the following drugs is strictly contraindicated due to the potential for severe drug interaction effects:</strong></p><p><u>Astemizole, cisapride, domperidone, pimozide and terfenadine</u></p><p>Elevated cisapride levels have been reported in patients receiving clarithromycin and cisapride concomitantly. This may result in QT prolongation and cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation and torsades de pointes. Similar effects have been observed in patients, taking clarithromycin and pimozide concomitantly (see section 4.3).</p><p>&nbsp;</p><p>Macrolides have been reported to alter the metabolism of terfenadine resulting in increased levels of terfenadine which has occasionally been associated with cardiac arrhythmias, such as QT prolongation, ventricular tachycardia, ventricular fibrillation and torsades de pointes (see section 4.3). In one study in 14 healthy volunteers, the concomitant administration of clarithromycin and terfenadine resulted in a 2 to 3-fold increase in the serum level of the acid metabolite of terfenadine and in prolongation of the QT interval which did not lead to any clinically detectable effect. Similar effects have been observed with concomitant administration of astemizole and other macrolides.</p><p>&nbsp;</p><p><u>Ergotamine/dihydroergotamine</u></p><p>Post-marketing reports indicate that co-administration of clarithromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterised by vasospasm, and ischaemia of the extremities and other tissues including the central nervous system. Concomitant administration of clarithromycin and these medicinal products is contraindicated (see section</p><p>4.3).</p><p>&nbsp;</p><p><u>Oral Midazolam</u></p><p>When midazolam was co-administered with clarithromycin tablets (500mg twice daily), midazolam AUC was increased 7-fold after oral administration of midazolam. Concomitant administration of oral midazolam and clarithromycin is contraindicated (see section 4.3).</p><p>&nbsp;</p><p><u>HMG-CoA Reductase Inhibitors (statins)</u></p><p>Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated (see section 4.3) as these statins are extensively metabolized by CYP3A4 and concomitant treatment with clarithromycin increases their</p><p>plasma concentration, which increases the risk of myopathy, including rhabdomyolysis. Reports of rhabdomyolysis have been received for patients taking clarithromycin concomitantly with these statins. If treatment with clarithromycin cannot be avoided, therapy with lovastatin or simvastatin must be suspended during the course of treatment.</p><p>&nbsp;</p><p>Caution should be exercised when prescribing clarithromycin with statins. In situations where the concomitant use of clarithromycin with statins cannot be avoided, it is recommended to prescribe the lowest registered dose of the</p><p>statin. Use of a statin that is not dependent on CYP3A metabolism (e.g. fluvastatin) can be considered. Patients should be monitored for signs and symptoms of myopathy.</p><p><strong>&nbsp;</strong></p><p><strong>Effects of other Medicinal Products on Clarithromycin</strong></p><p>Drugs that are inducers of CYP3A (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St John&rsquo;s wort) may induce the metabolism of clarithromycin.</p><p>This may result in sub-therapeutic levels of clarithromycin leading to reduced efficacy. Furthermore, it might be necessary to monitor the plasma levels of the CYP3A inducer, which could be increased owing to the inhibition of</p><p>CYP3A by clarithromycin (see also the relevant product information for the CYP3A4 inducer administered). Concomitant administration of rifabutin and clarithromycin resulted in an increase in rifabutin, and decrease in</p><p>clarithromycin serum levels together with an increased risk of uveitis.</p><p>&nbsp;</p><p>The following drugs are known or suspected to affect circulating concentrations of clarithromycin; clarithromycin dosage adjustment or consideration of alternative treatments may be required.</p><p>Efavirenz, nevirapine, rifampicin, rifabutin and rifapentine Strong inducers of the cytochrome P450 metabolism system such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine may accelerate the metabolism of clarithromycin and thus lower the plasma levels of clarithromycin, while increasing those of 14-OH-clarithromycin, a metabolite that is also microbiologically active. Since the microbiological activities of clarithromycin and 14-OH-clarithromycin are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of clarithromycin and enzyme inducers.</p><p>&nbsp;</p><p><u>Etravirine</u></p><p>Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, 14-OH-clarithromycin, were increased. Because 14- OH-clarithromycin has reduced activity against <em>Mycobacterium avium</em> complex (MAC), overall activity against this pathogen may be altered;</p><p>therefore alternatives to clarithromycin should be considered for the treatment of MAC.</p><p>&nbsp;</p><p><u>Fluconazole</u></p><p>Concomitant administration of fluconazole 200 mg daily and clarithromycin 500 mg twice daily to 21 healthy volunteers led to increases in the mean steady-state minimum clarithromycin concentration (Cmin) and area under the curve (AUC) of 33% and 18% respectively. Steady state concentrations of the active metabolite 14-OH-clarithromycin were not significantly affected by concomitant administration of fluconazole. No clarithromycin dose adjustment is necessary.</p><p>&nbsp;</p><p><u>Ritonavir</u></p><p>A pharmacokinetic study demonstrated that the concomitant administration of ritonavir 200 mg every eight hours and clarithromycin 500 mg every 12 hours resulted in a marked inhibition of the metabolism of clarithromycin. The clarithromycin Cmax increased by 31%, Cmin increased 182% and AUC increased by 77% with concomitant administration of ritonavir. An essentially complete inhibition of the formation of 14-OH-clarithromycin was noted.</p><p>Because of the large therapeutic window for clarithromycin, no dosage reduction should be necessary in patients with normal renal function.</p><p>However, for patients with renal impairment, the following dosage adjustments should be considered: For patients with creatinine clearance 30 to 60 mL/min the dose of clarithromycin should be reduced by 50%. For patients</p><p>with creatinine clearance &lt;30 mL/min the dose of clarithromycin should be decreased by 75%. Doses of clarithromycin greater than 1000 mg/day should not be co-administered with ritonavir.</p><p>&nbsp;</p><p>Similar dose adjustments should be considered in patients with reduced renal function when ritonavir is used as a pharmacokinetic enhancer with other HIV protease inhibitors including atazanavir and saquinavir (see section below, Bidirectional drug interactions).</p><p><strong>&nbsp;</strong></p><p><strong>Effect of clarithromycin on Other Medicinal Products</strong></p><p><u>CY3A4-based interactions</u></p><p>Co-administration of clarithromycin, which is known to inhibit CYP3A, and a drug primarily metabolised by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.</p><p>&nbsp;</p><p>The use of clarithromycin is contraindicated in patients receiving the CYP3A substrates astemizole, cisapride, domperidone, pimozide and terfenadine due to the risk of QT prolongation and cardiac arrhythmias, including ventricular tachycardia, ventricular fibrillation, and torsades de pointes (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p>The use of clarithromycin is also contraindicated with ergot alkaloids, oral midazolam, HMG CoA reductase inhibitors metabolised mainly by CYP3A4 (e.g. lovastatin and simvastatin), colchicine, ticagrelor and ranolazine (see section 4.3).</p><p>&nbsp;</p><p>Caution is required if clarithromycin is co-administered with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g. carbamazepine) and/or the substrate is extensively metabolized by this enzyme. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving clarithromycin. Drugs or drug classes that are known or suspected to be metabolized by the same CYP3A isozyme include (but this list is not comprehensive) alprazolam, carbamazepine, cilostazole, ciclosporin,</p><p>disopyramide, ibrutinib, methylprednisolone, midazolam (intravenous), omeprazole, oral anticoagulants (e.g. warfarin), atypical antipsychotics (e.g. quetiapine), quinidine, rifabutin, sildenafil, sirolimus, tacrolimus, triazolam</p><p>and vinblastine.</p><p>&nbsp;</p><p>Drugs interacting by similar mechanisms through other isozymes within the cytochrome P450 system include phenytoin, theophylline and valproate.</p><p>&nbsp;</p><p><u>Antiarrhythmics</u></p><p>There have been postmarketed reports of torsades de points occurring with the concurrent use of clarithromycin and quinidine or disopyramide.</p><p>Electrocardiograms should be monitored for QT prolongation during coadministration of clarithromycin with these drugs. Serum levels of quinidine and disopyramide should be monitored during clarithromycin therapy.</p><p>&nbsp;</p><p>There have been post marketing reports of hypoglycemia with the concomitant administration of clarithromycin and disopyramide. Therefore blood glucose levels should be monitored during concomitant administration of</p><p>clarithromycin and disopyramide.</p><p>&nbsp;</p><p><u>Oral hypoglycemic agents/Insulin</u></p><p>With certain hypoglycemic drugs such as nateglinide and repaglinide, inhibition of CYP3A enzyme by clarithromycin may be involved and could cause hypoglycaemia when used concomitantly. Careful monitoring of</p><p>glucose is recommended.</p><p>&nbsp;</p><p><u>Omeprazole</u></p><p>Clarithromycin (500 mg every 8 hours) was given in combination with omeprazole (40 mg daily) to healthy adult subjects. The steady-state plasma concentrations of omeprazole were increased (Cmax, AUC0-24, and t1/2</p><p>increased by 30%, 89%, and 34%, respectively), by the concomitant administration of clarithromycin. The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when omeprazole was coadministered with clarithromycin.</p><p>&nbsp;</p><p><u>Sildenafil, tadalafil and vardenafil</u></p><p>Each of these phosphodiesterase inhibitors is metabolised, at least in part, by CYP3A, and CYP3A may be inhibited by concomitantly administered clarithromycin. Co-administration of clarithromycin with sildenafil, tadalafil or vardenafil would likely result in increased phosphodiesterase inhibitor exposure. Reduction of sildenafil, tadalafil and vardenafil dosages should be considered when these drugs are co-administered with clarithromycin.</p><p>&nbsp;</p><p><u>Theophylline and carbamazepine</u></p><p>Results of clinical studies indicate that there was a modest but statistically significant (p&le; 0.05) increase of circulating theophylline or carbamazepine levels when either of these drugs were administered concomitantly with</p><p>clarithromycin. Dose reduction may need to be considered.</p><p>&nbsp;</p><p><u>Tolterodine</u></p><p>The primary route of metabolism for tolterodine is via the 2D6 isoform of cytochrome P450 (CYP2D6). However, in a subset of the population devoid of CYP2D6, the identified pathway of metabolism is via CYP3A. In this</p><p>population subset, inhibition of CYP3A results in significantly higher serum concentrations of tolterodine. A reduction in tolterodine dosage may be necessary in the presence of CYP3A inhibitors, such as clarithromycin in the CYP2D6 poor metaboliser population.</p><p>&nbsp;</p><p><u>Triazolobenzodiazepines (e.g. alprazolam, midazolam, triazolam)</u></p><p>When midazolam was co-administered with clarithromycin tablets (500 mg twice daily), midazolam AUC was increased 2.7-fold after intravenous administration of midazolam. If intravenous midazolam is co-administered</p><p>with clarithromycin, the patient must be closely monitored to allow dose adjustment. A drug-drug interaction study between oromucosal midazolam and clarithromycin has not been conducted. However drug delivery of</p><p>midazolam via oromucosal route, which could bypass pre-systemic elimination of the drug, will likely result in a similar interaction to that observed after intravenous midazolam rather than oral administration. The</p><p>same precautions should also apply to other benzodiazepines that are metabolised by CYP3A, including triazolam and alprazolam. For benzodiazepines which are not dependent on CYP3A for their elimination</p><p>(temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely.</p><p>&nbsp;</p><p>There have been post-marketing reports of drug interactions and central nervous system (CNS) effects (e.g. somnolence and confusion) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for</p><p>increased CNS pharmacological effects is suggested.</p><p><strong>&nbsp;</strong></p><p><strong>Other drug interactions</strong></p><p><u>Colchicine</u></p><p>Colchicine is a substrate for both CYP3A and the efflux transporter, Pglycoprotein (Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. When clarithromycin and colchicine are administered</p><p>together, inhibition of Pgp and/or CYP3A by clarithromycin may lead to increased exposure to colchicine. Concomitant use of clarithromycin and colchicine is contraindicated (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><u>Digoxin</u></p><p>Digoxin is thought to be a substrate for the efflux transporter, P-glycoprotein (Pgp). Clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are administered together, inhibition of Pgp by clarithromycin may</p><p>lead to increased exposure to digoxin. Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have also been reported in post-marketing surveillance. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias.</p><p>Serum digoxin concentrations should be carefully monitored while patients are receiving digoxin and clarithromycin simultaneously.</p><p>&nbsp;</p><p><u>Zidovudine</u></p><p>Simultaneous oral administration of clarithromycin tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. Because clarithromycin appears to interfere with the</p><p>absorption of simultaneously administered oral zidovudine, this interaction can be largely avoided by staggering the doses of clarithromycin and zidovudine to allow for a 4-hour interval between each medication. This</p><p>interaction does not appear to occur in paediatric HIV-infected patients taking clarithromycin suspension with zidovudine or dideoxyinosine. This interaction is unlikely when clarithromycin is administered via intravenous infusion.</p><p>&nbsp;</p><p><u>Phenytoin and valproate</u></p><p>There have been spontaneous or published reports of interactions of CYP3A inhibitors, including clarithromycin with drugs not thought to be metabolized by CYP3A (e.g. phenytoin and valproate). Serum level determinations are recommended for these drugs when administered concomitantly with clarithromycin. Increased serum levels have been reported.</p><p><strong>&nbsp;</strong></p><p><strong>Bi-directional drug interactions</strong></p><p>&nbsp;</p><p><u>Atazanavir</u></p><p>Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction. Co-administration of clarithromycin (500 mg twice daily) with atazanavir (400 mg once daily) resulted in a 2-fold increase in exposure to clarithromycin and a 70% decrease in exposure to 14-OH-clarithromycin, with a 28% increase in the AUC of atazanavir. Because of the large therapeutic window for clarithromycin, no dosage reduction should be necessary in patients with normal renal function.</p><p>For patients with moderate renal function (creatinine clearance 30 to 60 mL/min), the dose of clarithromycin should be decreased by 50%. For patients with creatinine clearance &lt;30 mL/min, the dose of clarithromycin should be decreased by 75% using an appropriate clarithromycin formulation. Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors.</p><p>&nbsp;</p><p><u>Calcium Channel Blockers</u></p><p>Caution is advised regarding the concomitant administration of clarithromycin and calcium channel blockers metabolized by CYP3A4 (e.g. verapamil, amlodipine, diltiazem) due to the risk of hypotension. Plasma concentrations of clarithromycin as well as calcium channel blockers may increase due to the interaction. Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients taking clarithromycin and verapamil concomitantly.</p><p>&nbsp;</p><p><u>Itraconazole</u></p><p>Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, leading to a bi-directional drug interaction. Clarithromycin may increase the plasma levels of itraconazole, while itraconazole may increase the plasma levels of clarithromycin. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged pharmacologic effect.</p><p>&nbsp;</p><p><u>Saquinavir</u></p><p>Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction. Concomitant administration of clarithromycin (500 mg twice daily) and saquinavir (soft gelatin capsules, 1200 mg three times daily) to 12 healthy volunteers resulted in steady-state AUC and Cmax values of saquinavir which were 177% and 187% higher than those seen with saquinavir alone. Clarithromycin AUC and Cmax values were approximately 40% higher than those seen with clarithromycin alone. No dose adjustment is required when the two drugs are co-administered for a limited time at the doses/formulations studied.</p><p>Observations from drug interaction studies using the soft gelatin capsule formulation may not be representative of the effects seen using the saquinavir hard gelatin capsule. Observations from drug interaction studies performed with saquinavir alone may not be representative of the effects seen with saquinavir/ritonavir therapy. When saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on</p><p>clarithromycin (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>The safety of clarithromycin for use during pregnancy has not been established. Based on variable results obtained from studies in mice, rats, rabbits and monkeys, the possibility of adverse effects on embyofoetal</p><p>development cannot be excluded. Therefore, use during pregnancy is not advised without carefully weighing the benefits against risk.</p><p><strong>&nbsp;</strong></p><p><strong>Lactation</strong></p><p>The safety of clarithromycin use during breast-feeding of infants has not been established. Clarithromycin is excreted into human breast milk.</p><p><strong>&nbsp;</strong></p><p><strong>Fertility</strong></p><p>There is no data available on the effect of clarithromycin on fertility in humans. In the rat, fertility studies have not shown any evidence of harmful effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data on the effect of clarithromycin on the ability to drive or use machines. The potential for dizziness, vertigo, confusion and disorientation, which may occur with the medication, should be taken into account before patients drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a. Summary of the safety profile</strong></p><p>The most frequent and common adverse reactions related to clarithromycin therapy for both adult and pediatric populations are abdominal pain, diarrhea, nausea, vomiting and taste perversion. These adverse reactions are usually mild in intensity and are consistent with the known safety profile of macrolide antibiotics (see section b of section 4.8).</p><p>&nbsp;</p><p>There was no significant difference in the incidence of these gastrointestinal adverse reactions during clinical trials between the patient population with or without preexisting mycobacterial infections.</p><p><strong>&nbsp;</strong></p><p><strong>b. Tabulated summary of adverse reactions</strong></p><p>The following table displays adverse reactions reported in clinical trials and from post-marketing experience with clarithromycin immediate-release tablets, granules for oral suspension, powder for solution for injection, extended release tablets and modified-release tablets.</p><p>&nbsp;</p><p>The reactions considered at least possibly related to clarithromycin are displayed by system organ class and frequency using the following convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100) and not known (adverse reactions from post-marketing experience; cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness when the seriousness could be assessed.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common (&ge;1/10</strong></p></td><td style="vertical-align:top"><p><strong>Common &ge; 1/100 to &lt; 1/10</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon &ge;1/1,000 to &lt; 1/100</strong></p></td><td style="vertical-align:top"><p><strong>Not Known (cannot be estimated from the available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Cellulitis<sup>1</sup>, candidiasis, gastroenteritis<sup>2</sup>, infection<sup>3</sup>, vaginal infection</p></td><td style="vertical-align:top"><p>Pseudomembranous colitis, erysipelas</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Leukopenia, neutropenia<sup>4</sup>, thrombocythemia<sup>3</sup>, eosinophilia<sup>4</sup></p></td><td style="vertical-align:top"><p>Agranulocytosis, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylactoid reaction<sup>1</sup>, Hypersensitivity</p></td><td style="vertical-align:top"><p>Anaphylactic reaction, angioedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anorexia, decreased appetite</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Anxiety, nervousness<sup>3</sup></p></td><td style="vertical-align:top"><p>Psychotic disorder, confusional state, depersonalisation, depression, disorientation, hallucination, abnormal dreams, mania</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dysgeusia, headache, taste perversion</p></td><td style="vertical-align:top"><p>Loss of consciousness<sup>1</sup>, dyskinesia<sup>1</sup>, dizziness, somnolence<sup>6</sup>, tremor</p></td><td style="vertical-align:top"><p>Convulsion, ageusia, parosmia, anosmia, paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vertigo, hearing, impaired, tinnitus</p></td><td style="vertical-align:top"><p>Deafness</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Cardiac arrest<sup>1</sup>, atrial fibrillation<sup>1</sup>, electrocardiogram QT prolonged<sup>7</sup>, extrasystoles<sup>1</sup>, palpitations</p></td><td style="vertical-align:top"><p>Torsade de pointes</p><p>, ventricular tachycardia<sup>7</sup>ventricular fibrillation</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vasodilation<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hemorrhage</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorder</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Asthma<sup>1</sup>, epistaxis<sup>2</sup>, pulmonary embolism<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Diarrhea, vomiting, dyspepsia, nausea, abdominal pain</p></td><td style="vertical-align:top"><p>Esophagitis<sup>1</sup>, gastrooesophageal reflux disease<sup>2</sup>, gastritis, proctalgia<sup>2</sup>, stomatitis, glossitis, abdominal distension<sup>4</sup>, constipation, dry mouth, eructation, flatulence</p></td><td style="vertical-align:top"><p>Pancreatitis acute, tongue discolouration, tooth discoloration</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Liver function test abnormal</p></td><td style="vertical-align:top"><p>Cholestasis<sup>4</sup>, hepatitis<sup>4</sup>, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased<sup>4</sup></p></td><td style="vertical-align:top"><p>Hepatic failure, jaundice hepatocellular</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash, hyperhidrosis</p></td><td style="vertical-align:top"><p>Dermatitis bullous<sup>1</sup>, pruritus, urticaria, rash maculo-papular<sup>3</sup></p></td><td style="vertical-align:top"><p>Severe cutaneous adverse</p><p>reactions (SCAR) (e.g. acute</p><p>generalised exanthematous</p><p>pustulosis, Stevens-Johnson</p><p>syndrome, toxic epidermal</p><p>necrolysis, drug rash with</p><p>eosinophilia and systemic</p><p>symptoms (DRESS)), acne</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Muscle spasms<sup>3</sup>, musculoskeletal stiffness<sup>1</sup>, myalgia<sup>2</sup></p></td><td style="vertical-align:top"><p>Rhabdomyolysis<sup>2, **</sup>, myopathy</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blood creatinine increased<sup>1</sup>, blood urea increased<sup>1</sup></p></td><td style="vertical-align:top"><p>Renal failure, nephritis interstitial</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Injection site phlebitis<sup>1</sup></p></td><td style="vertical-align:top"><p>Injection site pain<sup>1</sup>, injection site inflammation<sup>1</sup></p></td><td style="vertical-align:top"><p>Malaise<sup>4</sup>, pyrexia<sup>3</sup>, asthenia, chest pain<sup>4</sup>, chills<sup>4</sup>, fatigue<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Albumin globulin ratio abnormal<sup>1</sup>&nbsp;, blood alkaline phosphatase increased<sup>4</sup>, blood lactate dehydrogenase increased<sup>4</sup></p></td><td style="vertical-align:top"><p>International normalised ratio increased, prothrombin time prolonged, urine color abnormal</p></td></tr></tbody></table><p>* Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Patient exposure is estimated to be greater than 1 billion patient treatment days for clarithromycin.</p><p>** In some reports of rhabdomyolysis, clarithromycin was administered concomitantly with other drugs known to be associated with rhabdomyolysis (such as statins, fibrates, colchicine or allopurinol).</p><p>&nbsp;</p><p><sup>1</sup>&nbsp;ADRs reported only for the Powder for Solution for Injection formulation</p><p><sup>2</sup>ADRs reported only for the Extended-Release Tablets formulation</p><p><sup>3</sup>&nbsp;ADRs reported only for the Granules for Oral Suspension formulation</p><p><sup>4</sup>&nbsp;ADRs reported only for the Immediate-Release Tablets formulation</p><p>&nbsp;</p><p><strong>c. Description of selected adverse reactions</strong></p><p>Injection site phlebitis, injection site pain, vessel puncture site pain, and injection site inflammation are specific to the clarithromycin intravenous formulation.</p><p>&nbsp;</p><p>In some of the reports of rhabdomyolysis, clarithromycin was administered concomitantly with statins, fibrates, colchicine or allopurinol (see section 4.3 and 4.4).</p><p>&nbsp;</p><p>There have been post-marketing reports of drug interactions and central nervous system (CNS) effects (e.g. somnolence and confusion) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested (see section 4.5).</p><p>&nbsp;</p><p>There have been rare reports of clarithromycin ER tablets in the stool, many of which have occurred in patients with anatomic (including ileostomy or colostomy) or functional gastrointestinal disorders with shortened GI transit times. In several reports, tablet residues have occurred in the context of diarrhea. It is recommended that patients who experience tablet residue in the stool and no improvement in their condition should be switched to a different clarithromycin formulation (e.g. suspension) or another antibiotic.</p><p>&nbsp;</p><p>Special population: Adverse Reactions in Immunocompromised Patients (see section e)</p><p>&nbsp;</p><p><strong>d. Paediatric populations</strong></p><p>Clinical trials have been conducted using clarithromycin paediatric suspension in children 6 months to 12 years of age. Therefore, children under 12 years of age should use clarithromycin paediatric suspension.</p><p>&nbsp;</p><p>Frequency, type and severity of adverse reactions in children are expected to be the same as in adults.</p><p>&nbsp;</p><p><strong>e. Other special populations</strong></p><p><em>Immunocompromised patients</em></p><p>In AIDS and other immunocompromised patients treated with the higher doses of clarithromycin over long periods of time for mycobacterial infections, it was often difficult to distinguish adverse events possibly associated with clarithromycin administration from underlying signs of Human Immunodeficiency Virus (HIV) disease or intercurrent illness.</p><p>&nbsp;</p><p>In adult patients, the most frequently reported adverse reactions by patients treated with total daily doses of 1,000 mg and 2,000 mg of clarithromycin were: nausea, vomiting, taste perversion, abdominal pain, diarrhea, rash, flatulence, headache, constipation, hearing disturbance, Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic Pyruvate Transaminase (SGPT) elevations. Additional low-frequency events included dyspnoea, insomnia and dry mouth. The incidences were comparable for patients treated with 1,000 mg and 2,000 mg, but were generally about 3 to 4 times as frequent for those patients who received total daily doses of 4,000 mg of clarithromycin.</p><p>&nbsp;</p><p>In these immunocompromised patients, evaluations of laboratory values were made by analysing those values outside the seriously abnormal level (i.e. the extreme high or low limit) for the specified test. On the basis of these criteria, about 2% to 3% of those patients who received 1,000 mg or 2,000 mg of clarithromycin daily had seriously abnormal elevated levels of SGOT and SGPT, and abnormally low white blood cell and platelet counts. A lower percentage of patients in these two dosage groups also had elevated Blood Urea Nitrogen levels. Slightly higher incidences of abnormal values were noted for patients who received 4,000 mg daily for all parameters except White Blood Cell.</p><p><u>&nbsp;</u></p><p><strong><u>Please report adverse drug events to: </u></strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.saGo to top of the page</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports indicate that the ingestion of large amounts of clarithromycin can be expected to produce gastrointestinal symptoms. One patient who had a history of bipolar disorder ingested eight grams of clarithromycin and showed altered mental status, paranoid behaviour, hypokalemia, and hypoxaemia.</p><p>&nbsp;</p><p>Adverse reactions accompanying overdosage should be treated by the prompt elimination of unabsorbed drug and supportive measures. As with other macrolides, clarithromycin serum levels are not expected to be appreciably</p><p>affected by haemodialysis or peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antibacterial for systemic use, macrolide</p><p>ATC-Code: J01FA09</p><p>Clarithromycin is a semi-synthetic macrolide antibiotic obtained by substitution of the hydroxyl group in position 6 by a CH3O group in the erythromycin lactonic ring. Specifically, clarithromycin is 6-O-methyl</p><p>erythromycin A.</p><p>&nbsp;</p><p>Clarithromycin exerts its antibacterial action by binding to the 50S ribosomal subunits of susceptible bacteria and suppressing protein synthesis.</p><p><em>&nbsp;</em></p><p><em>Microbiology</em>: Clarithromycin has demonstrated excellent <em>in vitro </em>activity against standard strains of bacteria and clinical isolates. It is highly potent against a wide variety of aerobic and anaerobic Gram-positive and Gramnegative organisms. The minimum inhibitory concentrations (MICs) of clarithromycin are generally one log2 dilution more potent than the MICs of erythromycin.</p><p><em>&nbsp;</em></p><p><em>In vitro </em>data also indicate clarithromycin has excellent activity against <em>Legionella pneumophila</em>, and <em>Mycoplasma pneumoniae</em>. It is bactericidal to <em>Helicobacter pylori</em>; this activity of clarithromycin is greater at neutral pH</p><p>than at acid pH. <em>In vitro </em>and <em>in-vivo </em>data show that this antibiotic has activity against clinically significant mycobacterial species.</p><p>&nbsp;</p><p>The <em>in vitro </em>antibacterial spectrum of clarithromycin is as follows. Please see</p><p>below for table of MIC breakpoints.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>USUALLY SENSITIVE</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>NON-SENSITIVE</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>BACTERIA</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>BACTERIA</u></p><p>&nbsp;</p><p>&nbsp;</p><p><em>Streptococcus agalactiae&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</em>Enterobacteriacae</p><p><em>Streptococcus pyogenes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pseudomonas species</em></p><p><em>Streptococcus viridans</em></p><p><em>Streptococcus pneumoniae</em></p><p><em>Haemophilus influenzae</em></p><p><em>Haemophilus parainfluenzae</em></p><p><em>Neisseria gonorrhoea</em></p><p><em>Listeria monocytogenes</em></p><p><em>Legionella pneumophila</em></p><p><em>Pasteurella multocida</em></p><p><em>Mycoplasma pneumoniae</em></p><p><em>Helicobacter (Campylobacter) pylori</em></p><p><em>Campylobacter jejuni</em></p><p><em>Chlamydia pneumoniae (TWAR)</em></p><p><em>Chlamydia trachomatis</em></p><p><em>Moraxella (Branhamella) catarrhalis</em></p><p><em>Bordetella pertussis</em></p><p><em>Borrelia burgdorferi</em></p><p><em>Staphylococcus aureus</em></p><p><em>Clostridium perfringens</em></p><p><em>Peptococcus niger</em></p><p><em>Propionibacterium acnes</em></p><p><em>Bacterioides melaninogenicus</em></p><p><em>Mycobacterium avium</em></p><p><em>Mycobacterium leprae</em></p><p><em>Mycobacterium kansaii</em></p><p><em>Mycobacterium chelonae</em></p><p><em>Mycobacterium fortuitum</em></p><p><em>Mycobacterium intracellulare</em></p><p>&nbsp;</p><p>The principal metabolite of clarithromycin in man and other primates is a microbiologically-active metabolite, 14-OH-clarithromycin. This metabolite is as active or 1 to 2 fold less active than the parent compound for most organisms, except for <em>H. influenzae </em>against which it is twice as active. The parent compound and the 14-OH-metabolite exert either an additive or synergistic effect on <em>H. influenzae</em>. In guinea pigs with Legionella infection,</p><p>an intraperitoneal dose of 1.6 mg/kg/day of clarithromycin was more effective than 50 mg/kg/day of erythromycin.</p><p><em>Susceptibility Tests</em>: Quantitative methods that require measurement of zone diameters give the most precise estimate of susceptibility of bacteria to antimicrobial agents. One recommended procedure uses disc impregnated</p><p>with 15 mcg of clarithromycin for testing susceptibility (Kirby-Bauer diffusion test); interpretations correlate inhibition zone diameters of this disc test with MIC value for clarithromycin. The MICs are determined by the broth or agar dilution method. The recommended test medium for susceptibility testing of <em>Haemophilus influenzae </em>according to the National Committee of Clinical Laboratory Standards (NCCLS) is the Haemophilus Test Medium (H.T.M.).</p><p>&nbsp;</p><p>The correlation of disc inhibition zone diameters with MICs is given in the following Table:</p><p><u>Clarithromycin Interpretative Standards</u></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Inhibition Zone</p><p>Diameter (mm)</p><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>MIC (mcg/ml)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Organisms</p></td><td style="vertical-align:top"><p>S&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;I &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;R</p></td><td style="vertical-align:top"><p>S</p></td><td style="vertical-align:top"><p>I</p></td><td style="vertical-align:top"><p>R</p></td></tr><tr><td style="vertical-align:top"><p>All Organisms</p><p>(except <em>Haemophilus </em>and Staphylocci)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&ge; 18 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14-17 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&le; 13</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &le; 1</p><p>&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;2-4</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge; 8</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Staphylococci</p></td><td style="vertical-align:top"><p>&ge;20 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;---- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&le; 19</p></td><td style="vertical-align:top"><p>&le; 0.5</p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge; 1</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae </em>when tested on</p><p>HTM*</p></td><td style="vertical-align:top"><p>&ge; 13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ----&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &le; 10</p></td><td style="vertical-align:top"><p>&le; 8</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>&ge; 32</p></td></tr><tr><td style="vertical-align:top"><p>* HTM = Haemophilus Test Medium</p></td><td style="vertical-align:top"><p>S = Susceptible</p><p>I = Intermediate</p><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>R = Resistant</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>With these procedures, a report from the laboratory of &quot;susceptible&quot; indicates that the infecting organism is likely to respond to therapy. A report of &quot;resistant&quot; indicates that the infective organism is not likely to respond to therapy. A report of &quot;Intermediate Susceptibility&quot; suggests that the therapeutic effect of the drug may be equivocal or that the organism would be susceptible if higher doses were used (latter also referred to as moderately susceptible).</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Breakpoints</em></strong></p><p>The following breakpoints for clarithromycin, separating susceptible organisms from resistant organisms, have been established by the European Committee for Antimicrobial Susceptibility Testing (EUCAST).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Breakpoints (MIC, mcg/ml)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Microorganism</strong></p></td><td style="vertical-align:top"><p>Susceptible (&le;)</p></td><td style="vertical-align:top"><p>Resistant (&lt;)</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus </em>spp.</p></td><td style="vertical-align:top"><p>0.25 mcg/ml</p></td><td style="vertical-align:top"><p>0.5 mcg/ml</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus </em>spp.</p></td><td style="vertical-align:top"><p>1 mcg/ml</p></td><td style="vertical-align:top"><p>2 mcg/ml</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus </em>spp.</p></td><td style="vertical-align:top"><p>1 mcg/ml</p></td><td style="vertical-align:top"><p>32 mcg/ml</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top"><p>0.25 mcg/ml</p></td><td style="vertical-align:top"><p>0.5 mcg/ml</p></td></tr></tbody></table><p>&nbsp;</p><p>Clarithromycin is used for the eradication of <em>H. pylori</em>; minimum inhibitory concentration (MIC) &le; 0.25 mcg/ml which has been established as the susceptible breakpoint by the Clinical and Laboratory Standards Institute (CLSI).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The non-linear kinetics of orally administered clarithromycin have been studied extensively in a number of animal species and adult humans. These studies have shown that clarithromycin is readily and rapidly absorbed with an</p><p>absolute bioavailability of approximately 50%. No accumulation was found and the metabolic disposition did not change in any species following multiple dosing.</p><p>&nbsp;</p><p>Results of these animal studies showed that clarithromycin levels in all tissues, except the central nervous system, were several times higher than the circulating drug levels. The highest concentrations were usually found in the</p><p>liver and lung where the tissue to plasma (T/P) ratios reached 10 to 20.</p><p><em>&nbsp;</em></p><p><em>In vitro </em>studies showed that the protein binding of clarithromycin in human plasma averaged about 70% at concentrations of 0.45 - 4.5 mcg/ml. A decrease in binding to 41% at 45.0 mcg/ml suggested that the binding sites</p><p>might become saturated, but this only occurred at concentrations far in excess of the therapeutic drug levels.</p><p>&nbsp;</p><p>Clarithromycin and its 14-OH-metabolite distribute readily into the body tissues and fluids. Limited data from a small number of patients suggest that clarithromycin does not achieve significant levels in cerebro-spinal fluid</p><p>(CSF) after oral doses (i.e. only 1 to 2 percent of serum levels in CSF in patients with normal blood-CSF barriers). Concentrations in tissues are usually several fold higher than serum concentrations. Examples from tissue</p><p>and serum concentrations are presented below:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONCENTRATION</p><p>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(after 250 mg q 12h)</p><p>&nbsp;</p><p><strong>Tissue Type &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tissue&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Serum</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(mcg/g) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(mcg/ml)</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp; Tonsil &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.8</p><p>&nbsp;&nbsp; Lung &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.8 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7</p><p>&nbsp;</p><p>With b.i.d dosing at 250 mg, the peak steady state plasma concentration was attained in 2 to 3 days and averaged about 1 mcg/ml for clarithromycin and 0.6 mcg/ml for 14-OH-clarithromycin, while the elimination half-lives of the parent drug and metabolite were 3 - 4 hours and 5 - 6 hours, respectively.</p><p>With b.i.d dosing at 500 mg, the steady state Cmax for clarithromycin and its hydroxylated metabolite averaged 2.7- 2.9 mcg/ml and 0.88 - 0.83 mcg/ml, respectively. The half-life of the parent drug at the 500mg dose level was 4.5 -</p><p>4.8 hours, while that of the 14-OH-clarithromcyin was 6.9 - 8.7 hours. At steady state, the 14-OH-clarithromycin levels did not increase proportionately with the clarithromycin dose, and the apparent half-lives of both clarithromycin and its hydroxylated metabolite tended to be longer at the higher doses. This non-linear pharmacokinetic behaviour of clarithromycin, coupled with the overall decrease in the formation of 14-hydroxylation and Ndemethylation product at the higher doses, indicate that metabolism of clarithromycin approaches saturation at high doses.</p><p>&nbsp;</p><p>A pharmacokinetic study was conducted with clarithromycin 500 mg t.i.d. and omeprazole 40 mg q.i.d. When clarithromycin was given alone at 500 mg q8h, the mean steady-state Cmax value was approximately 31% higher and Cmin value was approximately 119% higher than when clarithromycin is compared with a previous study at 500mg q12h. The mean AUC 0-24 for clarithromycin was 65% greater when 500 mg clarithromycin was given q8h rather than q12h. Neither Tmax nor half-life values appeared substantially different between the q8h and q12h regimens.</p><p>&nbsp;</p><p>When clarithromycin was administered with omeprazole, increases in omeprazole half-life and AUC0-24 were observed. For all subjects combined, the mean omeprazole AUC0-24 was 89% greater and the harmonic mean for</p><p>omeprazole t1/2 was 34% greater when omeprazole was administered with clarithromycin than when omeprazole was administered alone. When clarithromycin was administered with omeprazole, the steady state Cmax Cmin</p><p>and AUC0-8 of clarithromycin were increased by 10%, 27%, and 15%, respectively over values achieved when clarithromycin was administered with placebo.</p><p>In human adults given single oral doses of 250 mg or 1200 mg clarithromycin, urinary excretion accounted for 37.9% of the lower dose and 46.0% of the higher dose. Faecal elimination accounted for 40.2% and 29.1% of these</p><p>respective doses.</p><p>&nbsp;</p><p>At steady state, clarithromycin gastric mucus concentrations six hours after dosing were approximately 25-fold higher in the clarithromycin/omeprazole group compared with the clarithromycin alone group. Six hours post-dosing, mean clarithromycin gastric tissue concentrations were approximately 2-fold higher when clarithromycin was given with omeprazole than when clarithromycin was given with placebo.</p><p>&nbsp;</p><p>In a study comparing one group of healthy human subjects with a group of subjects with liver impairment who were given 250 mg of clarithromycin b.i.d for two days and a single 250 mg dose the third day, steady state plasma levels and systemic clearing of clarithromycin were not significantly different between the two groups. In contrast, steady state concentrations of the 14-OH metabolite were markedly lower in the group of hepatic-impaired subjects.</p><p>This decreased metabolic clearance of the parent compound by 14- hydroxylation was partially offset by an increase in the renal clearance of parent drug, resulting in comparable steady state levels of parent drug in the</p><p>hepatic impaired and healthy subjects. These results indicate that no adjustment of dosage is necessary for subjects with moderate or severe hepatic impairment but with normal renal function.</p><p>&nbsp;</p><p>A study was conducted to evaluate and compare the pharmacokinetic profile of multiple 500 mg oral doses of clarithromycin in subjects with normal and decreased renal function. This plasma levels, half-life, Cmax and Cmin for both clarithromycin and its 14-OH metabolite were higher and AUC was larger in subjects with renal impairment. Kelim and urinary excretion were lower. The extent to which these parameters differed was correlated with the degree of renal impairment: the more severe the renal impairment, the more significant the difference.</p><p>&nbsp;</p><p>Pharmacokinetics in elderly subjects: A study was also conducted to evaluate and compare the safety and pharmacokinetic profiles of multiple 500 mg oral doses of clarithromycin in healthy elderly male and female subjects to those in healthy young adult male subjects. In the elderly group, circulating plasma levels were higher and elimination slower than in the younger group for both parent drug and the 14-OH metabolite. However, there was no difference between the two groups when renal clearance was correlated with creatinine clearance. It is concluded from those results that any effect on the handling of clarithromycin is related to renal function and not to age <em>per se</em>.</p><p>Pharmacokinetics in patients with mycobacterial infections: Steady-state concentrations of clarithromycin and 14-OH-clarithromycin observed following administration of usual doses to adult patients with HIV infection</p><p>were similar to those observed in normal subjects. However, at the higher doses which may be required to treat mycobacterial infections, clarithromycin concentrations were much higher than those observed at the usual doses. In adult HIV-infected patients taking 2000 mg/day in two divided doses, steadystate clarithromycin C<em>max </em>values ranged from 5-10 mcg/ml. C<em>max </em>values as high as 27 mcg/ml have been observed in HIV-infected adult patients taking 4000 mg/day in two divided doses. Elimination half-lives appeared to be lengthened at these higher doses as compared to those seen with usual doses in normal subjects. The higher plasma concentrations and longer elimination half-lives observed at these doses are consistent with the known nonlinearity in clarithromycin pharmacokinetics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acute, subchronic and Chronic Toxicity: Studies were conducted in mice, rats, dogs and/or monkeys with clarithromycin administered orally. The duration of administration ranged from a single oral dose to repeated daily oral administration for 6 consecutive months.</p><p>In acute mouse and rat studies, 1 rat, but no mice, died following a single gavage of 5g/kg body weight. The median lethal dose, therefore, was greater than 5g/kg, the highest feasible dose for administration.</p><p>No adverse effects were attributed to clarithromycin in primates exposed to 100 mg/kg/day for 14 consecutive days or 35 mg/kg/day for 1 month.</p><p>Similarly, no adverse effects were seen in rats exposed to 75 mg/kg/day for 1 month, to 35 kg/day for 3 months, or 8 mg/kg/day for 6 months. Dogs were more sensitive to clarithromycin, tolerating 50 mg/kg/day for 14 days. 10</p><p>mg/kg/day for 1 and 3 months, and 4 mg/kg/day for 6 months without adverse effects.</p><p>The major clinical signs at toxic doses in these studies described above included emesis, weakness, reduced food consumption and weight gain, salivation, dehydration, and hyperactivity. Two of ten monkeys receiving 400</p><p>mg/kg/day died on treatment day 8; yellow discoloured faeces were passed on a few isolated occasions by some surviving monkeys given a dose of 400 mg/kg/day for 28 days.</p><p>The primary target organ at toxic dosages in all species was the liver. The development of hepatotoxocity in all species was detectable by early elevation of serum concentrations of alkaline phosphatase, alanine and aspartate</p><p>aminotransferase, gamma-glutamyl transferase, and/or lactic dehydrogenase.</p><p>Discontinuation of the drug generally resulted in a return to or toward normal concentrations of these specific parameters.</p><p>Additional tissues less commonly affected in the various studies included the stomach, thymus and other lymphoid tissues, and the kidneys. Conjunctival injection and lacrimation, following near therapeutic dosages, occurred in dogs only. At a massive dosage of 400 mg/kg/day, some dogs and monkeys developed corneal opacities and/or oedema.</p><p>Fertility, Reproduction, and Teratogenicity: Fertility and reproduction studies have shown daily dosages of 150-160 mg/kg/day to male and female rats caused no adverse effects on the oestrous cycle, fertility, parturition and a</p><p>number of viability of offspring. Two teratogenicity studies in both Wistar (p.o.) and Sprague-Dawley (p.o. and i.v.) rats, 1 study in New Zealand White rabbits and one study in cynomolgus monkeys failed to demonstrate any</p><p>teratogenicity from clarithromycin. Only in one additional study in Sprague- Dawley rats at similar doses and essentially similar conditions did a very low, statistically insignificant incidence (approximately 6%) of cardiovascular anomalies occur. These anomalies appeared to be due to spontaneous expression of genetic changes within the colony.</p><p>Two studies in mice also revealed a variable incidence of cleft palate (3-30%) following doses of 70 times the upper range of the usual daily human clinical dose (500 mg b.i.d), but not at the 35 times the maximal daily human clinical dose, suggesting maternal and foetal toxicity but not teratogenicity.</p><p>Clarithromycin has been shown to produce embryonic loss in monkeys when administered at approximately 10 times the upper range of the usual daily human dose (500 mg b.i.d), starting at gestation day 20. This effect has been attributed to maternal toxicity of the drug at very high doses. An additional study in pregnant monkeys at dosages of approximately 2.5 to 5 times the maximal intended daily dosage produced no unique hazard to the conceptus.</p><p>A dominant lethal test in mice given 1000 mg/kg/day (approximately 70 times the maximal human daily clinical dose) was clearly negative for any mutagenic activity, and, in a Segment I study of rats treated with up to 500</p><p>mg/kg/day (approximately 35 times the maximal daily human clinical dose) for 80 days, no evidence of functional impairment of male fertility due to this long-term exposure to these very high doses of clarithromycin was exhibited.</p><p>Mutagenicity: Studies to evaluate the mutagenic potential of clarithromycin were performed using both nonactivated and rat-liver-microsome-activated test systems (Ames Test). Results of these studies provided no evidence of mutagagenic potential at drug concentrations of 25 mcg/petri plate or less. At a concentration of 50 mcg, the drug was toxic for all strains tested.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maize Starch</p><p>Sodium Starch Glycollate</p><p>Calcium Hydrogen Phosphate</p><p>Hydroxypropyl Cellulose LF</p><p>Colloidal anhydrous silica</p><p>Talc</p><p>Magnesium Stearate</p><p>Opadry II OY-L-22906 Yellow</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg;C</p><p>Store in a dry place, protected from light</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clarimac 500mg Pack: White PVC-PVDC film / Aluminium foil blister pack of 7 Tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)
P.O.Box 442, Riyadh 11411
Fax: +966 11 265 0505
Email: contact@riyadhpharma.com
For any information about this medicinal product, please contact the local representative of marketing authorisation holder:
Saudi Arabia
Marketing department
Riyadh
Tel: +966 11 265 0111
Email: marketing@riyadhpharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>